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Sommario 
 
Introduzione: Il tumore alla prostata (PCa) è una delle neoplasie più 
comuni tra gli uomini nel mondo occidentale e, globalmente, rappresenta la 
sesta causa di morte dovuta a cancro. L'approccio diagnostico attuale si 
basa sulla misurazione dei livelli sierici dell’antigene prostatico PSA 
(prostate specific antigen), nonostante recenti studi clinici abbiano 
dimostrato che questo marcatore non riduce significativamente la mortalità 
associata a PCa. In questo scenario abbiamo ipotizzato che i microRNA 
possano essere nuovi potenziali biomarcatori di PCa.  
Scopo del lavoro: L'identificazione di microRNA, coinvolti nella 
progressione neoplastica del tumore prostatico come nuovi biomarcatori 
diagnostici aggiuntivi al PSA, prognostici e predittivi di aggressività 
tumorale. La nostra strategia sperimentale ha previsto l’uso di linee cellulari 
di prostata non tumorigeniche e a diverso grado di malignità, modelli murini 
di carcinoma prostatico e casistiche di pazienti affetti da PCa.  
Materiali e metodi: Linee cellulari commerciali: analisi dell'espressione 
globale dei miRNA tramite piattaforma low-density array nelle linee di PCa 
(LNCap, PC3, DU145), normali o iperplastiche (RWPE-1 e BPH-1). 
Casistiche cliniche: analisi di miRNA selezionati, in un set di pazienti (n=58) 
nei tessuti di parenchima normale, pre-neoplastico (prostatic intraepithelial 
neoplasia, PIN) e tumorale. I risultati ottenuti sono stati correlati a parametri 
clinicopatologici dei pazienti. I potenziali target proteici dei miRNA 
selezionati sono stati valutati in una casistica più ampia mediante tissue 
micro-array (TMA). Modello murino transgenico TRAMP: analisi globale di 
espressione dei miRNA in ghiandole di PIN e tumorali, e nello stroma 
associato. Linee cellulari primarie: ottenimento di linee di fibroblasti derivate 
da resezioni chirurgiche di PCa (n=10). 
Risultati: Dallo screening nelle linee cellulari abbiamo selezionato 23 
miRNA poi valutati nei 58 pazienti. Tredici miRNA hanno mostrato 
differenze di espressione significative (p<0.05). In particolare, nove miRNA 
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(miR-135b,-193a-5p,-205,-224,-22,-34b,-34c-5p,-452,miR-886-3p) sono 
risultati progressivamente diminuiti nella progressione neoplastica (N-PIN-
PCa). Viceversa, i miR-130a, -218, -532, -542-5p, -489 e let-7c hanno 
mostrato una diminuzione di espressione nel PIN rispetto al tessuto 
normale.  È noto che i miR-205, miR-218, miR-224 abbiano come bersaglio 
proteico RUNX2 (Runt-related transcription factor 2), un fattore di 
trascrizione coinvolto nel tropismo osseo di cellule metastatiche. 
La valutazione di RUNX2 nei TMA di prostata ha rivelato che la positività 
nucleare è specifica delle cellule tumorali (p<0.0001) e correla con 
l’estensione del tumore e con l'invasione capsulare. Inoltre il confronto tra 
l’espressione dei miRNA e RUNX2 ha mostrato correlazione inversa 
significativa. Dall’analisi del modello TRAMP abbiamo identificato un 
pannello di miRNA differenzialmente espressi tra le componenti epiteliali e 
stromali associate a PIN o PCa (n=52).  
Conclusioni: I nostri risultati mostrano una sinergica perdita di miRNA con 
funzione oncosoppressiva e contemporaneo aumento di RUNX2 nei tessuti 
di PCa. Questo dato ha importanti implicazioni a livello di progressione di 
malattia che sarà valutata in una successiva fase del progetto. Le nostre 
analisi hanno indicato il miR-205 come potenziale marcatore di aggressività 
di malattia. Hanno inoltre identificato 9 miRNA precocemente persi nelle 
lesioni precancerose (PIN) rispetto al parenchima sano. Studi in casistiche 
indipendenti potranno confermare queste molecole come nuovi 
biomarcatori di neoplasia da affiancare alla valutazione del PSA. Inoltre lo 
studio dei miRNA “stromali” ha evidenziato una profonda deregolazione di 
queste molecole nel microambiente tumorale rispetto a quello non 
neoplastico. Questo risultato sottolinea dal punto di vista molecolare 
l’importanza dello stroma nel sostenere la sopravvivenza e la crescita 
tumorale e fornisce una possibile strategia terapeutica alternativa, mirata 
alle cellule stromali anziché epiteliali per indurre regressione di malattia. 
Saranno necessari ulteriori studi per valutare il ruolo dei miRNA 
nell’interazione tra epitelio tumorale e stroma circostante.  
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Abstract 
 
Introduction: Prostate cancer (PCa) is one of the most common cancers 
among men and the sixth cause of cancer-related death in men worldwide. 
The current diagnostic approach is based on serum measurement of 
prostate specific antigen (PSA) levels, despite recent clinical studies 
showed that did not considerably reduced mortality incidence in prostate 
cancer patients. In this scenario, we hypothesized that microRNAs 
(miRNAs) could be novel biomarkers for PCa disease. 
Aim of the study: We propose to identify miRNA signatures associated to 
PCa progression that could represent a novel generation of diagnostic 
biomarkers adjunctive to PSA, prognostic and predictive of cancer 
progression. Our experimental strategy included the use of normal or 
tumorigenic prostate cell lines, mouse model of PCa and patients’ series.  
Methods: Prostate cell lines: global miRNA expression analysis using a 
low-density array platform in PCa (LNCap, PC3, DU145) or non-
tumorigenic cells (RWPE-1, BPH-1). Clinical series. Analysis of selected 
miRNAs in 58 PCa patients for which normal parenchyma and prostatic 
intraepithelial neoplasia (PIN) was available. Correlation of molecular 
profiles to clinicopathological characteristics. Potential miRNA targets were 
investigated using a larger series of PCa patients arranged in tissue micro-
arrays (TMAs). TRAMP mouse: global miRNA profiles were obtained from 
epithelial and stromal compartments of PIN or tumoral lesions. Primary cell 
lines: fibroblasts were obtained from prostate resection of PCa patients 
(n=10).   
Results: miRNA screening in cell lines provided a panel of 23 miRNAs that 
were then investigated in the 58 PCa patients. Thirteen miRNA displayed 
significant deregulation (p<0.05) in disease tissues. Specifically nine 
miRNAs (miR-135b,-193a-5p,-205,-224,-22,-34b,-34c-5p,-452, miR-886-
3p) were progressively down-regulated during neoplastic progression (N-
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PIN-PCa). Conversely, miR-130a, -218, -532, -542-5p, -489 and let-7c 
displayed lower levels in PIN compared to normal prostate. A recognized 
target of miR-205, miR-218 and miR-224 is the Runt-related transcription 
factor 2 (RUNX2), a protein involved in metastatic dissemination to the 
bone. In our patients’ TMA, RUNX2 was overexpressed in tumoral cell 
nuclei (p<0.0001) and it was related to tumor size and capsular invasion. 
Moreover RUNX2 was inversely related to miRNA levels. TRAMP mice 
analysis has provided a signature of miRNAs (n=52) differentially 
expressed in epithelial and stromal compartments of PIN or PCa cells.  
Conclusions: Our results show a simultaneous loss of oncosuppressive 
miRNAs and increased RUNX2 expression in PCa tissues. This data is 
particularly relevant in disease progression monitoring, an aspect that will 
be studied in future project’s phases. Our analysis showed that miR-205 
loss is a potential biomarker of aggressive disease. Furthermore, we 
identified nine miRNAs which expression is decreased from early stage of 
disease (PIN). Validation of this result in independent patients’ series could 
provide novel biomarkers of PCa useful as adjunts to PSA monitoring. 
Lastly, profound stromal miRNAs deregulation underlines the importance of 
tumour microenvironment in sustaining cancer cell survival and growth. 
Moreover this result suggest that targeting tumour stroma could represent 
an alternative strategy for anti-cancer therapies.  
Future studies are needed to shed light on this aspect.
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1. Prostate cancer 
Prostate cancer (PCa) is the most common cancer among men (Figure 1) 
with greater mortality among solid cancers (Figure 2). In the United States, 
PCa is expected to account for 28% (238.590) of the total new cancer 
cases and 10% (29.720) of the total cancer deaths in males in 2013, 
ranking second to lung cancer in cancer-related deaths. The probability of 
developing prostate cancer from birth to death is 16,15% (1 in 6) [1]. In 
Europe, the incidence of PCa is 22,8%. The mortality rate is 9,5% and in 
Italy it is the third cause of cancer death after lung and colon cancer [2]. 
Adenocarcinoma is the predominant histological type of prostate cancer 
and usually originates from the malignant transformation of glandular 
luminal epithelial cells.  
 
 
Figure 1: Most commonly diagnosed cancer among men worldwide, 2008 [3] 
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Figure 2: (a) International variation in age-standardized prostate cancer incidence 
rates; (b) International variation in age-standardized prostate cancer mortality rates 
Source: GLOBOCAN 2008 [3] 
 
1.1. Prostate cancer classification 
In order to classify prostate cancer grade, Donald F. Gleason in 1966 
created a unique grading system for prostatic carcinoma based on the 
architectural pattern of the tumor [4]. The Gleason grading system is 
substantially different from grading systems used for other solid neoplasms. 
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Most systems examine the morphology of individual cells, focusing on 
features such as nuclear size and pleomorphism, and the frequency of cells 
with chromatin aggregation, prominent nucleoli and mitoses. Although 
individual cells comprising tumors of higher Gleason score demonstrate 
such morphological changes, these are not integrated into the Gleason 
scoring system. Rather the Gleason system examines the relationship of 
cells to each other (a glandular architecture) without incorporating the 
morphology of individual cells in characterizing the malignancy (Figure 3).  
 
 
Figure 3: Gleason grading system 
 
Another innovative aspect of this system was that rather than assigning the 
worst grade as the grade of the carcinoma, the grade was defined as the 
sum of the two most common grade patterns and reported as the Gleason 
score [5]. The architecture of normal and hypertrophied prostate tissue 
consists of glands of epithelial cells surrounding a glandular lumen and 
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resting on a continuous, supportive layer of basal cells, all embedded 
inconnective tissue stroma. Disruption of the basal cell layer defines 
prostatic neoplasms, occurring partially in PIN and completely in cancer. 
Once the basal layer is lost, the Gleason score is used to evaluate the 
remaining epithelial cell glandular architecture [6].  
According to the 2005 ISUP (International Society of Urological Pathology) 
modifications, Gleason 3 cancer consists of discrete glandular units that 
vary in size and shape and populate the prostatic stroma in clustered 
fashion among non-neoplastic prostatic acini [5]. The individual tumor acini 
have a smooth and usually rounded edge with an intact basement 
membrane. In contrast, Gleason 4 cancer is comprised of ill defined, fused 
glands with poorly formed glandular lumina, often with irregular borders that 
raggedly infiltrate the stroma. Gleason pattern 5 represents the total loss of 
all glandular differentiation [5]. Although all patterns have in common a loss 
of their basal cell layer, the difference between Gleason patterns 3 and 4 is 
the focal loss of a rounded glandular architecture, the fusing of glands and 
the disruption of an otherwise smooth glandular border. The progressive 
difference between Gleason patterns 4 and 5 is the total loss of any 
recognizable rounded glandular form, this being replaced with sheets of 
cancerous cells [6] 
1.2.  Prostatic intraepithelial neoplasia (PIN)  
High-grade prostatic intraepithelial neoplasia (HGPIN) is the only accepted 
precursor of prostatic adenocarcinoma, according to numerous studies of 
animal models and man; other proposed precursors include atrophy and 
malignancy-associated changes (with no morphological changes). PIN is 
characterized by progressive abnormalities of phenotype and genotype that 
are intermediate between benign prostatic epithelium and cancer, indicating 
impairment of cell differentiation and regulatory control with advancing 
stages of prostatic carcinogenesis. The only method of detection of PIN is 
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biopsy because it does not significantly elevate serum prostate-specific 
antigen concentration and cannot be detected by ultrasonography [7]. 
PIN is characterized by cellular proliferation within pre-existing ducts and 
acini, with cytological changes mimicking cancer, including nuclear and 
nucleolar enlargement (Figure 4, Table 1). There is an inversion of the 
normal orientation of epithelial proliferation from the basal cell compartment 
to the luminal surface, similar to adenomas in the colon [7].  
 
 
Figure 4: High-grade PIN, micropapillary pattern [7]. 
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  Low-grade PIN  High-grade PIN  
Architecture Epithelial cells 
crowding and 
stratification, with 
irregular spacing 
Similar to low-grade PIN; 
More crowding and 
stratification; four patterns: 
tufting, micropapillary, 
cribriform, and flat 
Cytology 
Nuclei Enlarged, with 
marked size 
variation 
Enlarged; some size and 
shape variation 
Chromatin Normal Increased density and 
clumping 
Nucleoli Rarely prominent* Prominent 
Basal cell layer Intact May show some disruption 
Basement membrane Intact Intact 
*Fewer than 10% of cells have prominent nucleoli. 
Table 1: Diagnostic criteria of PIN [7] 
In its original description, PIN was subcategorized into three grades, with 
grade 1 equating to LGPIN (low-grade PIN) and grades 2 – 3 combined into 
HGPIN (high-grade PIN). 
Prostatic intraepithelial neoplasia is found predominantly in the peripheral 
zone of the prostate (75 – 80%), rarely in the transition zone (10 – 15%), 
and very rarely in the central zone (5%). This distribution mirrors the 
frequency of the zonal predilection for carcinoma of the prostate (PCa). The 
frequency of HGPIN in needle biopsy series ranges from 5 to 16%. HGPIN 
is relatively uncommon in TURP (transurethral resection of the prostate), 
with studies reporting a rate of 2.3% and 2.8%, respectively [8]. The 
prevalence of HGPIN in radical prostatectomy specimens is remarkably 
high; it was present in 85 – 100% of specimens, reflecting the strong 
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association between the lesion and PCa [9]. There are other two possible 
findings in prostate that may be premalignant: adenosis (atypical 
adenomatous hyperplasia) and proliferative inflammatory atrophy (PIA). 
The data for these are much less convincing than those for HGPIN. If 
adenosis and PIA are removed from the list of precursor lesions of PCa, 
there remains only one well established precursor to PCa, that is HGPIN 
[8]. 
1.3.  Diagnosis 
Currently, the diagnostic method is based on the quantification of PCa 
serum prostate-specific antigen (PSA), supported by digital rectal 
examination (DRE), subsequently confirmed by ago biopsy. The PSA test 
measures the blood level of the enzyme (<4 ng / mL normal,> 4 ng / mL 
increased risk of cancer), however, blood levels of PSA may vary for many 
reasons other than cancer. Two common causes of increased levels of 
PSA are the benign prostatic hyperplasia (BPH) and the prostatitis. 
Although the method of screening with PSA is widely used, recent studies 
have shown that screening with PSA did not significantly reduce mortality 
associated with PCa. This is due to the low specificity of this method [10]. 
In order to have a clear diagnosis, the biopsy supports the evaluation of the 
PSA, to perform a histological sample analysis. In the event that has been 
diagnosed PCa, current therapeutic approaches include prostatectomy and 
radiation therapy, for localized PCa, and androgen deprivation therapy 
(ADT) in advanced stages treatment. Currently is not yet available a 
targeted therapy for advanced disease, and androgen-independent 
cytotoxic chemotherapy is the current choice of treatment in spite of his 
limited effectiveness. The lack of available treatment options for efficiently 
eradicating advanced PCa makes the development of alternative methods 
urgent. Understanding the molecular alterations that distinguish progressive 
disease from non-progressive disease will help identify novel prognostic 
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markers or therapeutic targets. In fact, new target therapies are developing 
to damage cancer cells specifically. 
1.4. Androgen Receptor 
Androgens play a critical role in the development of the male phenotype 
during sexual differentiation but also in the development and progression of 
PCa [11]. Androgenic effect in the prostate is primarily mediated by 
dihydrotestosterone (DHT), which derives predominantly from the reduction 
of testicular testosterone, but also adrenal dihydroepiandrosterone (DHEA) 
catalyzed by locally produced 5α-reductase enzymes [12]. The cellular 
response to androgens is mediated via the AR, a ligand-inducible 
transcription factor that comprises a C-terminal ligand-binding domain 
(LBD), a highly conserved DNA-binding domain, a hinge region and N-
terminal transactivation domain [11]. Upon ligand binding, cytosolic AR 
undergoes conformational changes, including interaction of the N- and C-
terminal domains and dissociation from heat shock proteins, enabling the 
AR to interact with co-regulatory molecules such as ARA70 and importin-α, 
which promote nuclear translocation and dimerization (Figure 5) [13]. In the 
nucleus, AR binds to the promoters of androgen-regulated genes (ARGs), 
such as prostate-specific antigen (PSA) and recruits various coactivators 
and RNA polymerase II to induce transcription [14]. This classic genomic 
mode of AR action promotes the transcription of a variety of genes 
encoding proteins necessary for the development, growth and maintenance 
of a healthy prostate [15].  
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Figure 5: Classic androgen receptor (AR) genomic activity via androgen. 
Androgens derive predominantly from the testis (90–95%) but also to a lesser 
extent from the adrenal glands (5–10%) and mediate their effects via binding to the 
AR. Testicular testosterone (T) and adrenal DHEA or androstenedione are 
converted locally in the prostate into bioactive DHT by the enzymes 5α-reductase 1 
and 2. In the classic mode of AR genomic activity, androgen binding to the AR 
induces a conformational change that leads to the dissociation of chaperone and 
heat shock proteins (HSP40, HSP90) and its subsequent interaction with co-
regulatory molecules and importin-α, which promote nuclear translocation of AR–
ligand complexes. In the nucleus, the AR undergoes phosphorylation and 
dimerization, which permits chromatin binding to androgen-responsive elements 
(ARE) within androgen-regulated target genes. The AR recruits a variety of 
coactivators (ARA70, SRC-1, -3, and CBP/p300) and RNA polymerase II (Pol II) to 
induce gene transcription [15]. 
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1.5. Therapy  and castration resistant prostate cancer (CRPC) 
Identification of new therapeutic targets for CRPC has mainly resulted from 
an improved understanding of tumor biology. Tumor-derived factors, host 
factors, and tumor microenvironment are all essential contributors in 
sustaining prostate tumor growth and progression of metastases, triggering 
clinical development of novel therapeutics, including those targeting 
hormonal signaling, angiogenesis, bone-derived factors, cell cycle 
checkpoints, activated tyrosine kinases, and host immune surveillance. 
Although patients with CRPC have, by definition, castrate levels of 
circulating testosterone, most tumors continue to remain dependent on 
androgen and on signaling from the androgen receptor (AR). This may 
occur through constitutive activation of the AR gene amplification, 
alternative splicing [16]  
Although <5% of patients present with metastatic disease, up to 40% of 
men eventually develop metastases despite local treatment [16]. 
Metastases are frequently osseous, can cause substantial pain, and 
increase the risk for fractures and other skeletal related events (SREs). 
Once metastases have developed, PCa is incurable, and all treatment is 
palliative.  
Surgical or medical castration is highly effective in shrinking tumor burden, 
decreasing prostate-specific antigen (PSA) levels, enhancing the quality of 
life, and improving survival [16]. However, most patients will eventually 
experience disease progression despite the castration, with a median 
duration of response of 12–24 month [16].  
Androgen deprivation therapy (ADT) for prostate cancer (PCa) represents 
one of the most effective systemic palliative treatments known for solid 
tumors. Although clinical trials have assessed the role of ADT in patients 
with metastatic disease, the risk–benefit ratio, especially in earlier stages, 
remains poorly defined. Given the mounting evidence for potentially life-
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threatening adverse effects with short- and long-term ADT, it is important to 
redefine the role of ADT for this disease [17]. 
 
Figure 6:  Landscape of castration-resistant prostate cancer. AR= androgen 
receptor [16] 
 
Although  some patients will respond initially to secondary hormonal 
manipulations, castration-resistant prostate cancer (CRPC) will inevitably 
improve [16]. Following hormonal manipulations, cytotoxic chemotherapy 
had been the only treatment shown to improve survival for patients with 
CRPC [18], [19]. In 1996, mitoxantrone was the first chemotherapy to show 
a palliative benefit for patients with CRPC in combination with steroids 
compared with steroids alone (29% vs 12%; p = 0,01) [20]. Although no 
survival benefit was seen with mitoxantrone in two phase 3 trials [20][21], it 
was the first chemotherapy to be approved by the US Food and Drug 
Administration (FDA) for the treatment of men with CRPC. 
Although docetaxel plus prednisone extended survival compared to 
mitoxantrone, the overall benefit was modest, with most patients 
experiencing disease progression within 7 months. Hence, the focus since 
2004 has been on trying to improve clinical outcomes by exploring 
Introduction 
13 
 
alternative chemotherapy agents, novel targeted agents, and sequential 
and combination regimens. Within the past year, several promising agents 
with widely varied mechanisms of action and therapeutic targets have 
demonstrated efficacy, and four new drugs were FDA approved for the 
treatment of patients with CRPC (cabazitaxel, sipuleucel-T, denosumab, 
and abiraterone acetate). The understanding of advanced PCa has 
changed in parallel with the expansion of the repertoire of therapeutic 
options (Figure 6). 
1.6. TRAMP mice 
Historically, a variety of models including cell lines, transgenics, 
transplantable tumors, and chemically and hormonally induced tumors have 
been used to test strategies for prevention and treatment of prostate 
cancer. Each of these model systems has strengths and merit, and each 
presents specific windows of opportunity for research. The primary 
advantages of using transgenic mice for pre-clinical testing are: (1) the 
cancer arises autochthonously within the appropriate microenvironment; (2) 
mice possess an intact immune system; (3) heterogeneous cancers arise 
de novo and can change with time or as a consequence of selective 
pressure in contrast to more static systems where tumors simply grow from 
clonal cancer cells often derived from late stage disease or metastases. 
While cancer in mice may only approximate cancer in men, the degree to 
which cancer in transgenic mice will reflect the natural history of clinical 
prostate cancerbe related to  I) the strain of mice, II) the nature of the 
transgene construct, III) the site of integration IV) the temporal and spatial 
pattern of transgene expression. Fortunately, most of these variables can 
be controlled or modified [22]. 
The model TRAMP (Transgenic Adenocarcinoma of Mouse Prostate) is a 
transgenic mouse that, differently from other mouse models, uniformly and 
spontaneously develops prostate cancer after the onset of puberty [22]. 
Introduction 
14 
 
The TRAMP mouse has been established as an excellent mouse model of 
prostate cancer because spontaneously develop prostatic adenocarcinoma 
that progresses through multiple stages and that exhibits both histological 
and molecular features similar to that of human prostate cancer [22]. Male 
TRAMP mice express a PB-Tag transgene consisting of the minimal 
−426/+28 bp regulatory element of the rat probasin promoter directing 
prostate-specific epithelial expression of the simian virus 40 early genes to 
abrogate the activity of p53 and Rb tumor suppressor genes. Loss of 
functional p53 and Rb predisposes epithelial cells to enhanced survival 
signals and allows investigation of molecular pathways and targets. 
Prostate cancer progresses in this model in an androgen-dependent 
fashion and is highly reproducible. The transgene is hormonally regulated 
by androgens, thus temporally, transgene expression correlates with sexual 
maturity [23]. By approximately 6 weeks, TRAMP mice exhibit low-grade 
PIN, which progresses to HGPIN by 12 weeks. Focal adenocarcinoma 
develops between 12 and 18 weeks, and progresses to poorly 
differentiated carcinoma within 24 weeks. By 28 weeks of age, 100% of 
these transgenic mice, without any treatment, harbor metastatic prostate 
cancer in the liver, lymph nodes, lungs, and occasionally in bone [22], [23] 
(Figure 7). 
 
 
Figure 7: Cancer progression in TRAMP mouse 
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1.7.  microRNAs 
MicroRNAs (miRNAs) are small, non-coding, endogenous RNAs that 
repress translation of genes post-transcriptionally [24], [25]. They are 
single-stranded RNA molecules of 20-23-nucleotides (nt) length that control 
gene expression in many cellular processes. These molecules typically 
reduce the translation and stability of mRNAs, including those of genes that 
mediate processes in tumorigenesis, such as inflammation, cell cycle 
regulation, stress response, differentiation, apoptosis, and invasion. miRNA 
targeting is initiated through specific base-pairing interactions between the 
5' end ("seed" region) of the miRNA and sites within coding and 
untranslated regions (UTRs) of mRNAs; target sites in the 3' UTR lead to 
more effective mRNA destabilization. Since miRNAs frequently target 
hundreds of mRNAs, miRNA regulatory pathways are complex.  
1.7.1. microRNAs: biogenesis and function 
Most miRNAs are transcribed as large primary transcripts (pri-miRNAs) by 
RNA polymerase II [26]. These structured RNAs are then processed into 
60–70 nt hairpin loop precursors (pre-miRNAs) by the nuclear RNase III 
protein, Drosha, in concert with the enzyme called DGCR8 [27]. 
 
 
Figure 8:  The miRNA biogenesis pathway in animals [27] 
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Pre-miRNAs are exported into the cytoplasm by Exportin-5 (Figure 8). 
Another RNase III enzyme, Dicer, to generate duplex forms of miRNAs, 
then processes the pre-miRNAs again. Following the maturation of 
miRNAs, one strand of the duplex is incorporated into the RNA-induced 
silencing complex (RISC) containing Argonaute 2 (Ago2), creating the 
inhibitory complex on the target mRNA (Figure 9) [28], [29]. 
 
 
Figure 9: Traditional and non-traditional concepts for the biogenesis and function 
of miRNA. The traditional miRNA biogenesis pathway is designated with a normal 
arrow while non-traditional pathways are designated with dotted arrow. Canonical 
animal pri-miRNA is transcribed by RNA polymerase II and processed into pre-
miRNA by the Drosha/DGCR8 enzyme complex in the nucleus. Then the pre-
miRNA is exported into the cytoplasm in concert with Exportin-5. In the cytoplasm, 
Dicer cleaves pre-miRNA to a duplex form of miRNAs. Finally, one strand of the 
duplex is incorporated into the RNA-induced silencing complex to enable inhibition 
of translation of the target mRNA. Non-traditional miRNAs can be generated via 
Drosha- or Dicer-independent pathways. Some miRNAs can induce gene 
expression by targeting the gene's promoter. 
 
. 
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The first evidence for the existence of miRNAs as well as their important 
regulatory role has been obtained by the discovery of the small 
endogenous RNA lin-4 as an essential regulator of cell-fate determination 
in the C. Elegans larvae. This effect of lin-4 was caused by its ability to 
downregulate the expression of the transcription factor lin-14, whose 
temporal decrease is critical during the L1–L3 larval cell stage progression 
[30] [31]. An additional proof for the ability of miRNAs to regulate gene 
expression has been obtained by the discovery of second miRNA, let-7,  
that controls L3-L4 larvae cell stage progression during C. elegans 
development by targeting lin-41 [32] [32][33]. Since the discovery of let-7, 
more than 1000 different miRNAs have been described and annotated in 
various organisms ranging from algae to humans (www.mirbase.org) [34]. 
miRNA genes are encoded within the genome, suggesting that their 
transcription might be tightly coordinated with the transcription of other 
genes including the protein-coding genes that serve either as a source of 
miRNAs or as their targets. The genomic origin of miRNAs raises the 
question about the mechanism that either supports or discriminates against 
simultaneous expression of protein-coding genes and miRNAs. The most 
common mechanism of transcriptional segregation between specific 
protein-coding genes and miRNA gene relies on the localization of ~50% of 
mammalian miRNA-coding genes within the intergenic space. Most of the 
intergenic miRNAs are autonomously expressed and hold their own 
enhancer and promoter elements [35] [36] [31]. Similar to protein coding 
genes, most miRNA genes are transcribed by RNA Polymerase II (RNA Pol 
II) [37]. It is therefore likely that temporal- and lineage-specific differences 
in miRNA and protein-coding gene expression are controlled by the 
expression of specific transcription factors and post-translational chromatin 
modifications. This possibility is particularly plausible because of the cluster 
organization of several miRNA genes. miRNA genes, that are clustered 
within 0.1–50 kb from each other, display common expression patterns [38]. 
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Common expression patterns of clustered miRNAs such as miRNAs from 
the miR-17-92 and miR-23-27a-24 cluster reflect their generation from a 
single PolII-dependent polycistronic transcript [26]. The coordinated miRNA 
gene expression may have functional significance as suggested by the 
ability of individual miRNAs derived from the miR-17-92 cluster to 
contribute simultaneously  to regulation of cell survival by targeting the pro-
apoptotic protein Bim [39]. Opposite to proximally located miRNA genes, 
miRNA genes that are spaced more than 50 kb apart tend to express in a 
non-coordinated fashion [38]. 
Approximately 40% of miRNA genes are localized within gene introns [40].  
Initiation of RNA Pol II- or, in some cases, RNA Pol III-dependent 
transcription [41], [42] within an intron may prevent transcription and 
splicing of the protein coding genes. However, experimental and 
bioinformatics data show the ability of numerous intronic miRNAs to 
coexpress with their host genes [38] [40] [43] [44]. It should be noted that 
the simultaneous presence of the miRNA and its host mRNA in a given 
tissue do not automatically imply co-transcription of the miRNA and its host 
gene(s). It could well be that transcription of the host genes and embedded 
in them miRNAs does not occur simultaneously but rather in a ‘seesaw’-like 
fashion, thus preventing potential impact of the intronic transcription on host 
gene splicing. Addressing this question would require GROseq analysis of 
mRNA and miRNA gene transcription [45]. 
Approximately 10% of known miRNA genes are situated within exons and, 
if encoded in sense direction with the coding gene, follow the transcription 
patterns of their host gene(s). It is plausible that miRNAs localized within 
the introns or exons of cell lineage- or function-specific genes might 
contribute to the control of genetic networks according to the expected 
function of the host gene product. The distinct evolutionary conservation of 
protein coding host genes and miRNAs suggest that localization of miRNAs 
within genes emerged in response to the environmental pressure that 
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required coordination of specific cell functions. In this respect, it would be 
interesting to determine the evolutionary traits of miRNAs in conjunction 
with the evolution of their hosts, as well as the appearance of novel 
regulatory networks in multicellular organisms [36]. 
Regardless of the genomic location, production of mature miRNAs occurs 
in a highly conserved fashion that involves the processing of the primary 
miRNA transcript in the nucleus to the mature product in the cell cytosol. 
The primary miRNA transcripts (pri-miRNAs) present themselves to the 
processing machinery not merely as specific sequences but rather as 
particularly shaped structures. This mode of RNA recognition reflects the 
ability of the pri-miRNA sequence to fold into an imperfectly paired, double-
stranded stem loop structure. The pri-miRNA transcripts can spawn a 
highly complex structure containing several multiple stem loops in a row. 
The nuclear microprocessor complex that contains two core proteins, 
Drosha and DGCR8, recognizes the imperfect pri-miRNA stem loop 
structures. DGCR8 recognizes and binds to the stem region of the pri-
miRNA hairpin followed by the recruitment of Drosha and ensuing cleavage 
of pri-miRNA and generation of the precursor-miRNA (pre-miR)  [46] [47]. 
The efficiency of pri-miRNA processing depends on the structural 
characteristics of single pri-miRNA sequences. In case that miRNAs that 
derive from large polycistronic clusters, such as miR-17-92, the miRNAs 
inside the core of the highly compact tertiary structure are processed less 
efficiently than miRNAs on the surface of the structure [48]. The processing 
of pri-miRNAs occurs co-transcriptionally and rapidly produces a pool of 
~60–70-nt-long stem-loop pre-miRNAs [49]. The nascent pre-miRNAs are 
exported to the cytoplasm by the karyopherin protein family member 
Exportin-5 in a GTP-dependent manner [50]. Once in the cytoplasm, the 
pre-miRNA is incorporated into the RISC Loading Complex (RLC) where it 
is processed by the type III ribonuclease Dicer into a ~21-nt-long 
miRNA/miRNA* duplex [51]. The miRNA/miRNA* duplex is further 
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processed/unwound by members of the Argonaute family, giving raise to 
the mature, single-stranded ~21-nt-long miRNA [52]. The miRNA-
generating process described above is currently viewed as the canonical 
pathway and contributes to the production of most mammalian miRNAs. 
1.7.2. miRNA and cancer 
Cancer is caused by uncontrolled proliferation and the inappropriate 
survival of damaged cells, which results in tumor formation. Cells have 
developed several safeguards to ensure that cell division, differentiation 
and death occur correctly and in a coordinated fashion, both during 
development and in the adult body.  
Many regulatory factors switch on or off genes that direct cellular 
proliferation and differentiation. Damage to these genes, which are referred 
to as tumor-suppressor genes and oncogenes, is selected for in cancer.  
Most tumor- suppressor genes and oncogenes are first transcribed from 
DNA into RNA, and are then translated into protein to exert their effects. 
Recent evidence indicates that small non-protein-coding RNA molecules, 
called microRNAs (miRNAs), might also function as tumor suppressors and 
oncogenes [53]. They have been shown to control cell growth, 
differentiation and apoptosis; consequently, impaired miRNA expression 
has been implicated in tumor suppressors and oncogenes. miRNAs, as 
previously described, regulate gene expression at post-transcriptional level, 
by binding to the 3’UTR targets messenger RNA, thus inhibiting their 
translation into proteins ( Figure 10). miRNAs play fundamental roles in 
organisms development and differentiation. Strong evidence documents 
that miRNAs unbalances are involved in many diseases, including cancer. 
A rapidly increasing number of platforms have been developed for miRNA 
expression profiling and microarray analysis was the most common method 
carried out to identify tumor-specific miRNA signatures [54]. However, the 
arrivals of next generation sequencing (NGS) technologies have offered a 
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new approach in the identification of previously unknown miRNAs [55]. 
While miRNA array hybridization system is based in the accumulated 
knowledge of miRNA databases, NGS technologies allow the identification 
of new miRNA genes. In parallel, qRT-PCR has been established the most 
suitable technology to validate miRNA expression-profiling results. 
 Figure 10: miRNAs can function as tumor suppressors and oncogenes a –in 
normal tissue proper microRNA (miRNA) transcription, processing and binding to 
complementary sequences on the target mRNA results in the repression of target-
gene expression through a block in protein. The overall result is normal rates of 
cellular growth, proliferation, differentiation and cell death. b- The reduction or 
deletion of a miRNA that functions as a tumor suppressor leads to tumor formation. 
c - The amplification or overexpression of a miRNA that has an oncogenic role 
would also result in tumor formation. In this situation, increased amounts of a 
miRNA, which might be produced at inappropriate times or in the wrong tissues, 
would eliminate the expression of a miRNA-target tumor-suppressor gene (pink) 
and lead to cancer progression[53].  
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1.7.3. miRNA and prostate cancer 
The first miRNA expression profile in PCa was carried out by Porkka et al 
[56]. They performed an oligonucleotide array hybridization method to study 
the expression of 319 human miRNAs in PCa and found 51 miRNAs 
differentially expressed in PCa [56]. Further studies confirmed some of the 
results achieved by these authors, while others showed different 
expression profiles or identified new altered miRNAs.  
Table 2 describes those miRNA involved in the pathogenesis of PCa.  
Androgen ablation, the mainstay for management of advanced PCa, 
reduces symptoms in about 70–80 % of patients, but most tumors relapse 
within 2 years to an incurable castration resistant state, which is ultimately 
responsible for PCa mortality [57]. On the contrary, for early stage clinically 
localized disease, radical prostatectomy and radiotherapy are curative; 
therefore, the choice of the best treatment for a particular PCa is not trivial. 
For instance, serum PSA level, primary tumor stage and Gleason grade do 
not reliably predict the outcome for individual patients, and identification of 
molecular indicators of aggressiveness is still needed. Androgen signaling 
has been associated with miRNA expression, since some miRNAs have 
been found to modulate the androgen pathway and further classified 
prostate carcinomas according to castration resistance [56]. For instance, 
the expression of miR-125b [58], miR-21 [59] and miR-141 [60] is regulated 
by an androgen responsive element (ARE) which controls the upregulation 
of these miRNAs and consequently the inhibition of their targets. miR-331-
3p is also associated with regulation of androgen receptor (AR) pathway 
since overexpression of its target, ERBB-2, has been related to disease 
progression and AR signaling [61]. Some miRNAs  play an important role in 
PCa because modulate the expression of genes that regulate cell growth 
and apoptosis, others correlate with metastatic PCa (down-regulation of 
miR-16, miR-34a, miR-126*, miR-205, miR-146a and the up-regulation of 
miR-301 and miR-125b) [62]. Some miRNAs such as miR-141, miR-143 
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and miR-145, have been found to be involved in cancer-related cell 
migration. miR-141 expression, up-regulated in metastatic PCa, correlated 
with Gleason score [43], [62]. Loss of expression of miR-143 and miR-145 
is related to development and progression of PCa [63] and metastasis and 
also correlate with Gleason score [64]. MiR-200 family regulate the 
epithelial-mesenchymal transition (EMT) and is down-regulated in tumor 
tissues [65]. In fact, miR-203 is progressively lost in advanced metastatic 
PCa showing a linkage between its expression and an antimetastatic role 
[66]. Some other miRNAs were also related with Gleason score (miR-1, 
miR-31 and miR-205), tumor stage (miR-125b, miR-205 and miR-222), pT 
stage (miR-1), perineural invasion (PNI) status (miR-1, miR-10, miR-30c, 
miR-100, miR-125b and miR-224) and biochemical progression (miR-96) 
as show  
Table 3 [43]. 
MiR-126* inhibit the expression of prostein, which is frequently 
overexpressed in PCa. Interestingly, miR-126, which corresponds to the 
alternative miR-126* strand, was reported to be up-regulated in metastatic 
xenograft cell line, suggesting that strand selection mechanism could be 
involved in the development of metastasis [43]. Different approaches are 
being developed to modulate the gain or loss of miRNA functions. miRNAs 
which act as tumor suppressors, are usually down-regulated in cancer 
while miRNAs acting as oncogenes are commonly overexpressed; 
therefore, restoring its function, in the first case, or inhibiting its expression, 
in the second one, may become interesting therapeutic options. To date, 
there is no PCa model in this field. Cationic liposomes or polymer-based 
nanoparticle formulations can be developed to achieve the delivery of 
miRNA mimics, synthetic miRNAs which are able to restore miRNA function 
within the tumor cell [67]. Multiple approaches have been designed to 
achieve miRNAs down-regulation. One of these approaches consists in the 
introduction of an anti-miRNA oligonucleotide (AMO), which is able to 
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interact between miRNA and its target through competitive inhibition of 
base pairing. Introduction of a modified mRNA to carry multiple pairing sites 
for endogenous miRNAs, known as miRNA sponge, was also tested to 
inhibit the function of some miRNAs through its real targets [68]. In recent 
studies, they down-regulate oncogene miRNAs introducing a synthetic 
miRNA molecule (anti-miRNA or miRNA inhibitor) which is able to interact 
by complementarity with the endogenous miRNA and inhibit its function. In 
another study, several small organic molecules were also screened to find 
a potential inhibitor of miRNA function. Therefore, miRNA-based 
therapeutics offers promising results for cancer treatment although they are 
still far away from clinical application Several reports describe PCa-specific 
miRNA expression signatures, however, the kind of regulated miRNAs is 
diverse, and there is no agreement in which would be the miRNA-profiling 
signature of PCa.. Agreement exists among these studies in that the 
majority of miRNAs are down-regulated in the PCa samples [55], [56], [60], 
[69], [70]. Although a correlation to tumor stage and grade was described 
for several miRNAs their relevance as prognostic markers to predict hard 
clinical endpoints, like clinical failure or cancer-related death, remains 
limited [55], [71]–[73] [65]. However, there are promising approaches to 
correlate the altered expression of specific miRNAs and progression of the 
disease. These miRNAs represent potential factors for PCa diagnosis and 
prognosis and promising therapeutic tools. 
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miRNA Expression 
Predicted/validated 
target(s) 
Altered function 
miR-10a Up-reg. HOXA1 
Gene expression, cell 
differentiation 
miR-20a Up-reg. E2F1-3 Apoptosis 
miR-21 Up-reg. 
MARCKS, PDCD4, 
PTEN, TPM1, SPRY2, 
TIMP3, RECK 
Apoptosis, castrate 
resistant (CR) 
miR-24 Up-reg. FAF1 Apoptosis 
miR-25 Up-reg. PTEN 
Cell proliferation, cell 
cycle 
miR-31 Up-reg. Bcl-w, E2F6 Apoptosis, cell cycle 
miR-32 Up-reg. C9orf5, Bim Apoptosis 
miR-34b Up-reg. 
CDK6, CREB, c-MYC, 
MET 
Cell cycle, cell 
proliferation 
miR-96 Up-reg. FOXO1, hZIPs Apoptosis 
miR-106a Up-reg. RB1 Cell cycle 
miR-125b Up-reg. BAK1 
Apoptosis, AR, 
metastasis 
miR-141 Up-reg. Clock AR, metastasis 
miR-148a Up-reg. CAND1, MSK1 
Cell cycle, cell 
proliferation 
miR-181a-1 Up-reg. RB1, RBAK 
Cell cycle, tumor 
progression 
miR-182 Up-reg. 
FOXO1, FOXO3, 
BRCA1, hZIP1 
Apoptosis 
miR-194 Up-reg. DNMT3a, MeCP2 Genomic instability 
miR-200a/b Up-reg. β-catenin, SIRT1 EMT, cell growth 
miR-200c Up-reg. SEC23A, JAGGED1 
Cell growth, 
apoptosis, metastasis 
miR-210 Up-reg. 
EFNA3, MNT, HOXA1, 
APC, ELK3 
Hypoxia, cell 
proliferation, migration 
miR-214 Up-reg. EZH2, N-Ras, PTEN 
Cell cycle, cell 
proliferation 
miR-218 Up-reg. 
RAS, c-myc, Laminin 5 
β3, THAP2, SMARCA5, 
and BAZ2A 
Cell proliferation, 
apoptosis 
miR-224 Up-reg. KLK1, API-5 
Apoptosis, cell 
proliferation, invasion 
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miR-296 Up-reg. HMGA1 
Cell proliferation, 
invasion 
miR-345 Up-reg. BAG3 
Apoptosis, invasion, 
metastasis 
miR-375 Up-reg. Sec23A Cell proliferation 
miR-521 Up-reg. CSA DNA repair 
miR-26a 
Up and down-
reg. 
PLAG1, EZH2 
Apoptosis, cell 
proliferation, invasion 
miR-30c 
Up and down-
reg. 
BCL-9, MTA1 Metastasis 
miR-100 
Up and down-
reg. 
RAS, c-myc, Laminin 5 
β3, THAP2, SMARCA5, 
and BAZ2A 
Cell proliferation, 
apoptosis 
miR-125a 
Up and down-
reg. 
ERBB2, ERBB3 
Cell proliferation, 
apoptosis 
miR-195 
Up and down-
reg. 
CDK4, GLUT3, WEE1, 
CDK6, Bcl-2 
Cell cycle, cell 
proliferation, 
apoptosis 
miR-221 
Up and down-
reg. 
p27kip1 Cell cycle 
miR-222 
Up and down-
reg. 
p27kip1 Cell cycle 
miR-30b 
Up and down 
reg. 
GalNAc, Snail1 
Invasion, 
immunosuppression 
let-7-family Down-reg. Ras, Cdc25A, Cyclin D1 
Apoptosis, cell 
proliferation, cell cycle 
miR-1 Down-reg. 
Exportin-6, Tyrosine 
kinase 9, PNP 
Cell proliferation, 
invasion 
miR-7 Down-reg. ERBB2 
Cell proliferation, 
tumor progression 
miR-16 Down-reg. 
Bcl-2, cyclin D1 and D3, 
CDK1, CDK2 
Apoptosis, cell cycle, 
metastasis 
miR-22 Down-reg. PTEN 
Cell proliferation, cell 
cycle 
miR-23a/b Down-reg. 
Mitochondrial 
glutaminase 
Advantage in growth 
miR-27b Down-reg. CYP1B1, Notch1 
Hormone metabolism, 
cell proliferation 
miR-29a Down-reg. 
Dkk1, Kremen2, sFRP2, 
B7-H3 
Cell differentiation, 
immune response 
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miR-34a Down-reg. 
BCL-2,SIRT1,E2F3, N-
MYC, MET, CDK4-6, 
DLL1 
Apoptosis, 
proliferation, survival 
miR-34c Down-reg. 
CDK4, E2F3, MET, c-
MYC 
Apoptosis, cell 
proliferation 
miR-92 Down-reg. Bim Apoptosis 
miR-99a Down-reg. 
SMARCA, SMARCD1, 
mTOR 
Apoptosis, cell cycle 
miR-101 Down-reg. EZH2 
Cell proliferation, 
invasion 
miR-106b-
25 
Down-reg. MCM7 
Cell cycle, cell 
proliferation 
miR-107 Down-reg. Granulin Cell proliferation 
miR-126 Down-reg. 
CRK, Spred1, 
PIK3R2/p85-beta 
Cell proliferation, 
invasion, tumor 
progression 
miR-126* Down-reg. Prostein Metastasis 
miR-128a Down-reg. 
GOLM1, PHB, TROVE2, 
TMSB10 
Tumor progression, 
invasion 
miR-143 Down-reg. MYO6, ERK5, KRAS 
Cell proliferation, 
migration, metastasis 
miR-145 Down-reg. MYO6, MYC, BNIP3 
Cell migration, 
metastasis, apoptosis 
miR-146a Down-reg. CXCR4, ROCK1 CR, metastasis 
miR-203 Down-reg. 
ZEB2, Bmi, survivin, 
Runx2 
EMT, metastasis 
miR-205 Down-reg. 
ErbB3, E2F1, E2F5, 
ZEB2, Protein Kinase 
Cε, IL24, IL32 
Cell cycle, cell 
proliferation, 
apoptosis,EMT 
miR-223 Down-reg. NFI-A Cell differentiation 
miR-301a Down-reg. 
FOXF2, BBC3, PTEN, 
COL2A1 
Cell proliferation 
miR-320a Down-reg. ETS2 Tumor progression 
miR-330 Down-reg. E2F1 Apoptosis 
miR-331-3p Down-reg. ERBB2 Cell cycle 
miR-449a Down-reg. HDAC-1 
Cell cycle, 
apoptosis 
 
Table 2: miRNAs altered in PCa, their target and function [54] 
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miRNA Expression 
Prognosis 
parameter(s) 
Target 
miR-21 Up-reg. 
Castrate resistant PCa 
(CR) 
MARCKS 
miR-331-3p Down-reg. CR ERBB-2 
miR-141 Up-reg. CR, Gleason score Clock 
miR-146 Down-reg. CR, metastasis CXCR4, ROCK1 
miR-125b Up-reg. 
CR, metastasis, tumor 
stage, perineural 
invasion (PNI) 
BAK1 
miR-96 Up-reg. 
Biochemical 
progression, tumor 
recurrence 
FOXO1, hZIPs 
miR-1 Down-reg. 
Gleason score, pT, 
recurrence 
XPO6, PTK9, PNP 
miR-143 Down-reg. Metastasis MYO6 
miR-145 Down-reg. Metastasis MYO6, MYC 
miR-16 Down-reg. Metastasis Bcl-2 
miR-34a Down-reg. Metastasis CD44 
miR-126* Down-reg. Metastasis Prostein 
miR-301 Down-reg. Metastasis 
FOXF2, BBC3, PTEN, 
COL2A1 
miR-200 
family 
Down-reg. 
Metastasis, Gleason 
score, tumor stage 
ZEB2, Bmi, survivin, Runx2, 
ErbB3, E2F1, E2F5, PKCɛ 
miR-221 Down-reg. 
Metastasis, 
TMPRSS2:ERG 
presence 
p27kip 
miR-10 Up-reg. PNI HOXA1 
miR-100 Up-reg. PNI 
RAS, c-myc, Laminin 5 β3, 
THAP2, SMARCA5, and 
BAZ2A 
miR-30c Up-reg. PNI BCL-9, MTA1 
miR-224 Up-reg. PNI KLK1, API-5 
 
Table 3: miRNAs implicated in PCa prognosis [54] 
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1.7.4. miRNAs as circulating biomarkers of PCa 
The biological function and the impact of circulating miRNAs on the tumor 
microenvironment and tumor progression remain to be investigated, and 
mechanisms of selective miRNA export from cells to the circulation system 
also remain to be uncovered. In one of the preliminary studies, they found 
that miR-21 and -221 levels in the patients were higher than in healthy 
controls, while, for the miR-141, no difference was observed [74]. In a 
recent review, the author underlines some lack in studies about circulating 
miRNA.. The first problem shown is that, both serum and plasma samples 
collected and processed under very different or partly indefinitely described 
conditions (various blood collection devices, time interval between 
phlebotomy and centrifugation, storage temperature during this period, 
centrifugation conditions, e.g. speed, duration, and temperature etc.) were 
uniformly defined as sources of ‘circulating’ miRNAs [75]. The pre-analytical 
differences of samplings alone give rise to distinctly interfering effects by 
varying levels of miRNAs from leukocytes, erythrocytes, and platelets, 
respectively. The true cell-free circulating miRNAs could be confounded by 
cellular miRNAs from blood cells released either from them or as 
contaminating cellular particles insufficiently removed by inappropriate 
centrifugation. Indeed only four miRNAs (miR-21, miR-141, miR-221, miR-
375) were found to be changed in at least two studies, but not always 
consistently in the same direction [75]. 
Others studies started to describe the expression profile of miRNAs also in 
serum [74]. In a recent study, they analyzed five miRNAs highly abundant 
in the sera of patients with metastatic disease (miRNA-375, miRNA-9*, 
miRNA-141, miRNA-200b and miRNA-516a-3p). Circulating miRNA-375 
and miRNA-141 turned out to be the most pronounced markers for high-risk 
tumors [63]. Their levels also correlated with high Gleason score or lymph-
node positive. In addition, the expression levels of miRNA-375 and miRNA-
141 were monitored in 72 prostate tissue samples (36 tumors vs. 36 
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benign). Both miRNAs were highly expressed in all samples and 
significantly upregulated in the tumors compared to normal tissues [63]. 
Overall, their observations suggest that miRNA-375 and miRNA-141 
expression is enhanced in prostate cancer specimens, and their release 
into the blood is further associated with advanced cancer disease. Another 
study evaluated three miRNAs (miR-141, miR-146b-3p and miR-194) high 
in patients who subsequently experienced BCR (biochemical recurrence) in 
the screening study. MiR-146b-3p and miR-194 were also associated with 
disease progression in the validation cohort. Multivariate analysis revealed 
that miR-146b-3p possessed prognostic information beyond standard clinic-
pathological parameters. Analysis of tissue cohorts revealed that miR-194 
was robustly expressed in the prostate, high in metastases, and its 
expression in primary tumors was associated with a poor prognosis [76].  
In Table 4 are summarized recent studies about circulating miRNA as 
biomarkers of PCa. 
Urine is also easily available source for molecular markers; therefore, 
detection of miRNAs in urine of patients with PCa would represent an ideal 
non-invasive diagnosis approach. 
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1.8. Prostate cancer cell lines 
Most of the studies on prostate cancer were done in cell lines that have 
been widely used for research purposes and proved the useful tool in the 
genetic approach, and its characterization shows that they are, in fact, an 
excellent model for the study of the biological mechanisms involved in 
cancer. 
Table 5 lists the non-neoplastic and tumor cell lines used in studies on 
prostate cancer. 
 
Table 5: Origins, characteristics and culture conditions of prostate epithelial cell 
lines 
Name Origin Characteristics
Benign cell lines
 BPH-1 Immortalized with SV40 AR-
 PWR-1E
Immortalized with human 
papilloma virus 18
AR+, androgen responsive, express 
PSA, nontumorigenic in nude mice
 RC-165N/hTERT
Immortalized with human 
telomerase reverse transcriptase
AR+, androgen responsive, express 
PSA, nontumorigenic in nude mice
 RWPE1 Immortalized with SV40
AR+, androgen responsive, express 
PSA, nontumorigenic in nude mice
AR+ PCa cell lines
 ARCaP
Ascites fluid of the same patient as 
MDA PCa cells
Low levels of AR and PSA, growth 
inhibited by androgens
 DUCaP Brain metastasis Wild-type AR, androgen sensitive
 E006AA
Primary PCa from an African-
American patient with hormone 
naïve localized PCa
Mutated AR, do not express PSA, 
insensitive to androgens
 LAPC Locally advanced or metastatic PCa
Wild-type AR, express PSA, 
different sublines available
 LNCaP Lymph node metastasis
Mutated AR, produce PSA, 
androgen responsive
 MDA PCa cells Bone metastasis
Mutated AR, produce PSA, less 
responsive to androgens
 PC346
Transurethral resection of 
localized advanced PCa
Wild-type AR, different sublines 
available
 22Rv1 Primary PCa Mutated AR, low levels of AR and 
 VCaP Bone metastasis Wild-type AR, androgen sensitive
AR- PCa cell lines
 DU145 Brain metastasis AR-, do not respond to androgens
 PC3 Bone metastasis AR-, do not respond to androgens
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The first human prostatic tumor epithelial cell lines to be spontaneously 
established were LNCaP, PC3 and DU145, which were derived from PCa 
lymph node, bone and brain metastases respectively and remain the most 
commonly used PCa cell lines [77]. Of these three cell lines, only LNCaP 
expresses significant levels of AR and consequently is the most widely 
used AR+ cell line. DU145 and PC3 cells are generally considered being 
AR− and thus usually used as AR− controls or to study androgen signaling 
by ectopic AR overexpression. Although LNCaPs are androgen responsive 
and produce PSA, it should be noted that they express a mutated AR 
(T877A), which results in altered AR signaling [15]. 
In contrast to the abundance of PCa cell lines, there are relatively few cell 
lines derived from benign prostatic epithelium suitable for investigating AR 
signaling. This is primarily due to difficulties in in-vitro immortalization and 
the terminally differentiated nature of the androgen-dependent luminal 
epithelium such that primary epithelial cultures predominantly exhibit an 
androgen-independent but proliferative basal/intermediate phenotype [78]. 
Nonetheless, there are currently three main AR+ normal prostate epithelial 
cell lines PWR-1E, RWPE1 and RC-165N/hTERT, which were immortalized 
using SV40, human papilloma virus 18 or human telomerase reverse 
transcriptase respectively [79]. These cell lines are androgen responsive, 
express AR and PSA but do not form tumors when injected into nude mice. 
This latter characteristic has been exploited to investigate the role of 
putative oncogenes and carcinogens on tumorigenesis indicating the 
suitability of these cell lines as a potential model system to study processes 
of oncogenic transformation. It should be noted, however, that the process 
of immortalization itself can result in genetic alterations and/or mutation 
[80]. To date, these cell lines have predominantly been used to compare 
gene expression levels and drug efficacy with PCa cell lines. In spite of the 
essential role of cancer cell lines in biomedical research, there is a debate 
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among the scientific community on the fact whether they are or not 
representative of the original tumor. 
1.9. RUNX2 expression in prostate cancer 
Runt-related transcription factors (RUNX) determine cell fate and regulate 
lineage-specific proliferation and differentiation [81],[82]. The RUNX gene 
family, which has been studied extensively, includes RUNX1, RUNX2 and 
RUNX3, closely related transcription factors that have crucial roles in both 
oncogenic and tumor-suppressive functions. RUNX1 is important for 
hematopoiesis, and its ablation leads to leukemia; RUNX3 is a critical 
regulator and its promoter hypermethylation is associated with several 
types of cancer [83][84]. These findings strongly suggest that RUNX1 and 
RUNX3 function as tumor suppressors. The RUNX2 gene, on the other 
hand, is a unique member of the RUNX family that was shown to have a 
dual function in several studies. RUNX2 is a transcription factor essential 
for osteoblast differentiation [85] and its ablation results in deregulated cell 
proliferation and immortalization, supporting its function as a tumor 
suppressor [84]. However, several studies report that RUNX2 is 
upregulated in prostate and breast cancer cells that metastasize to bone, 
indicating a correlation with cancer progression [86] and therefore an 
oncogenic function for RUNX2. 
RUNX2 is closely related to bone formation, and prostate cancer (CaP) is 
the most common cancer to metastasize to bone. Therefore, several 
studies focus on the role of RUNX2 in the tumor and bone tissue 
environments by using cell lines derived from metastatic bone lesions. Only 
a few studies have used human tissues to investigate the function of 
RUNX2 in CaP, and these studies report contradictory results [81][87][88]. 
1.10. Cancer associated fibroblasts (CAF) 
The prostate is composed of a number of different cell populations. The 
interaction between them is critical for the development and proper function 
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of the prostate. However, the effect of the molecular cross talk between 
these cells in the course of carcinogenesis is still unclear.  
The prostate is made of the epithelium and the stroma, which consists of 
smooth muscle cells (SMC), fibroblasts, nerves, and lymphatics [89]. The 
stroma plays an important role during embryonic development of diverse 
structures in the prostate. In adult tissues, stromal cells are responsible for 
the maintenance of homeostatic equilibrium and in controlling cell size and 
cell functions of the epithelium they surround. This is achieved through 
modifications of the extracellular matrix [90], [91]. In the case of disturbed 
homeostasis regulation, stromal cells can contribute to the initiation and 
progression of cancer [92]. During carcinogenesis, the stroma undergoes 
several changes. Altered fibroblasts, termed cancer-associated fibroblasts 
(CAF), appear in the proximity of the tumor, the amount of SMCs 
decreases, the bioavailability of growth factors increases, inflammatory 
cells are infiltrated, angiogenesis increases, and stromal protease inhibitors 
are lost [93], [94]. 
In a study, employing an approach wherein immortalized epithelial cells and 
immortalized human fibroblasts were cocultured, they show that normal 
associated fibroblasts (NAF) and cancer-associated fibroblasts (CAF) 
differentially influenced the growth and proliferation of immortalized human 
prostate epithelial cells [95]. Whereas NAFs inhibited the growth of 
immortalized epithelial cells but promoted the growth of metastatic PC-3 
cells, CAFs promoted the growth of immortalized epithelial cells but not of 
PC-3. Cytokine arrays revealed that NAFs secreted higher levels of tumor 
necrosis factor-alpha compared with CAFs whereas CAFs secreted higher 
levels of interleukin-6 (IL-6) compared with NAFs. The growth-inhibiting 
effects of NAFs were counteracted by the addition of IL-6, and the growth-
promoting effects exerted by the CAFs were counteracted by tumor 
necrosis factor-alpha. Furthermore, CAFs induced the migration of 
endothelial cells in an IL-6-dependent manner. Therefore, they show that 
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normal fibroblast cells have a protective function at very early stages of 
carcinogenesis by preventing immortalized epithelial cells from proliferating 
and forming new blood vessels, whereas CAFs aid immortalized epithelial 
cells to develop later. [95] 
Gandellini research group recently have focused on the involvement of 
microRNAs in tumor-stroma interplay. They found that miR-205, as already 
reported, is the most down-modulated miRNA in PCa cells upon CAF 
stimulation, due to direct transcriptional repression by HIF-1 (Hypoxia-
inducible factors), a known redox-sensitive transcription factor. Rescue 
experiments demonstrated that ectopic miR-205 overexpression in PCa 
cells counteracts CAF-induced EMT, thus impairing enhancement of cell 
invasion, acquisition of stem cell traits, tumorigenicity, and metastatic 
dissemination. In addition, miR-205 blocks tumor-driven activation of 
surrounding fibroblasts by reducing pro-inflammatory cytokine secretion. 
Overall, such findings suggest miR-205 as a brake against PCa metastasis 
by blocking both the afferent and efferent arms of the circuit between tumor 
cells and associated fibroblasts, thus interrupting the pro-oxidant and pro-
inflammatory circuitries engaged by reactive stroma. The evidence that 
miR-205 replacement in PCa cells is able not only to prevent but also to 
revert the oxidative/pro-inflammatory axis leading to EMT induced by CAFs, 
sets the rationale for developing miRNA-based approaches to prevent and 
treat metastatic disease [96]. This is the only work that addresses the issue 
of the role of miRNA on the interactions between fibroblasts and epithelial 
cells. Then it becomes essential to deepen the study of this kind of 
interaction. 
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2. AIM OF THE STUDY 
The current diagnostic approach of PCa is based on measurement of PSA 
serum levels. Although the method of screening with PSA is widely used, 
recent studies have shown that screening with PSA did not significantly 
reduce mortality associated with PCa. This is due to the low specificity of 
this method. In order to have a clear diagnosis, the biopsy supports the 
evaluation of the PSA, to perform a histological sample analysis. 
The lack of specific prostate cancer diagnosis methods shows the need to 
identify novel additional diagnostic and prognostic biomarkers. miRNA are 
involved in the regulation several physiological and pathological processes; 
therefore, the aim of this study is the identification of microRNA involved in 
PCa development from PIN in different study models.  
We propose to identify miRNA signatures associated to PCa progression 
that could represent a novel generation of diagnostic biomarkers adjunctive 
to PSA, prognostic and predictive of cancer progression. Our experimental 
strategy included the use of normal or tumorigenic prostate cell lines, 
mouse model of PCa and patients’ series.  
The next purpose will be to study in depth the interaction between epithelial 
cells and tumor associated fibroblasts, analyzing the role of miRNAs in the 
modulation of pathological processes. 
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3. MATERIAL AND METHODS 
3.1. Cell lines 
First, we analyzed the miRNA expression profile in 5 prostate cell lines. We 
choose 1 normal epithelial cell line (RWPE-1), 1 cell line of Benign prostatic 
hyperplasia (BPH-1) and 3 cancer cell lines (LNCap, DU145, PC3). The 
normal cell line (RWPE-1) is androgen sensitive and was cultured in K-SFM 
(Keratinocyte Serum Free Medium) with addition of 5 ng/ml of EGF (human 
recombinant epidermal growth factor) and 0.05 mg/ml of BPE (bovine 
pituitary extract). Other cell lines were cultured in RPMI supplemented with 
10% fetal bovine serum (FBS) and 1% Pen-Strep and were maintained at 
37°C and 5% CO2. We choose one cancer cell line androgen sensitive 
(LNCap) and the others two androgen insensitive, with high metastatic 
potential as shown in  
Table 6. 
Cell line Description Derived from metastatic site 
RWPE-1 epithelial normal prostate cell line 
 
BPH-1 Benign prostatic hyperplasia 
 
LNCap 
prostate cancer cell line androgen 
sensitive 
left supra clavicular lymph node 
DU145 
prostate cancer cell line- metastatic 
androgen insensitive 
brain 
PC3 prostate cancer cell line- metastatic bone 
 
Table 6: Prostate cancer and normal prostate cell lines 
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3.2. Human samples 
We selected 192 human samples of prostatic acinar adenocarcinoma, 
undergone radical prostatectomy from 2004 to 2006, 58 of which showed 
PIN. The clinical stage and histopathological variables of PCa diagnosis are 
displayed in Table 7. We also selected 8 patient with high grade prostate 
cancer (T4, Gleason score >7, N1) in order to analyse trough Laser capture 
microdissection (see below) the stromal component. 
 
 
Table 7: Clinical stage of 192 prostate cancers. 
 
3.2.1. Tissue microarray 
Whit this case study we built a Tissue Micro Array (MiniCore Alphelys ®). 
TMAs utilise cores, collected from multiple paraffin-embedded tissue 
‘donor’ blocks that are inserted (arranged in columns and rows of 
potentially hundreds of cases) into a single ‘recipient’ block. In Figure 11 
are shown all passages of TMA construction. Once the TMAs have been 
192 patients -Mean Age 65 (range 44-77)
Grading % (n) Regional Lymphnodes %(n)
T1 0.5 (1) N0 86.9 (167)
T2 64.1 (123) N1 8.4 (16)
T3 33.9 (65) Nx 4.6 (9)
T4 1.6 (3)
Perineural invasion %(n)
Yes 58.3 (112)
Gleason score % (n) No 29.2 (56)
5 2.6 (5)
6 29.7 (57) Capsular invasion %(n)
7 50.5 (97) L0 26.6 (51)
7a (3+4) (68) L1 7.8 (15)
7b (4+3) (29) L2 27.1 (52)
8 11.5 (22) L3 30.2 (58)
9 3.6 (7) nd 8.3 (16)
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constructed, they allow analysis of very large numbers of samples more 
quickly, efficiently and in a more cost-effective manner than examination of 
whole tissue sections for each marker.  
In each paraffin block, we put 1 core of non-neoplastic tissue, 3 cores of 
cancer, in order to reproduce tumor heterogeneity and different Gleason 
score in each patient, and 1 core, when present, of PIN. We built 16 
paraffin blocks and each core was 2mm diameter. In each block, we 
spotted cores from 12 patients for a total of 192 patients. From each TMA 
block, a 4µm section was cut and stained with haematoxylin and eosin stain 
(H&E) and subsequently with a specific immunohistochemical stain. 
 
 
Figure 11: TMA building a) Area selection and core pick up from donor block b) 
Core insertion into the recipient block c) 4 µm section cut d) TMA section on the 
slice 
 
Figure 12: PCa Tissue micro-array 
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3.3. TRAMP mouse 
Simultaneously we examined PIN and cancer in the TRAMP mouse model. 
In this part of the study, we examined a series of 5 transgenic mice, 
sacrificed at 24 weeks, which have all developed the adenocarcinoma. The 
animals were sacrificed and the urogenital tract, including the bladder, 
seminal vesicles and prostate, was collected and then formalin fixed and 
paraffin embedded. 
3.3.1. Laser-capture microdissection (LCM) 
The enrichment of stromal and epithelial component in TRAMP mice was 
accomplished through the LCM (Laser-Capture Microdissection, Leica 
LMD6000, Figure 13). Indeed, we collect from TRAMP mouse three 
sections 6 μm thick of FFPE (formalin-fixed, paraffin-embedded) tissues. 
The sections were stained only with haematoxylin in order to preserve 
nucleic acid stability. Moreover, Leica slides are made of a particular 
membrane that allows tissues to be cut from the laser without interfering 
with RNA/DNA purification.  
Each slice were deparaffinised and dehydrated following this steps: 
 Xylene 1’ 
 Absolute Ethanol 1’ 
 Ethanol  95% 1’ 
 Ethanol  75% 1’ 
 DEPC water 1’ 
 Haematoxylin Carazzi 1’ 
 DEPC water 1’ 
 Ethanol  75% 1’ 
 
Then we allow the section to dry for about 2 hours to follow with the laser 
microdissection. In Figure 14 are displayed examples of laser 
microdissection on TRAMP mouse tissues. 
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Figure 13: Laser capture microdissection (Leica microsystem) 
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Figure 14: TRAMP mouse laser microdissection. Panel A: PIN epithelium before 
laser cut. Panel B: PIN After laser cut. Panel C: Cancer at 24 weeks of age 
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3.4. RNA purification 
For molecular investigation, macrodissection of the tissues was performed 
by punching the archival blocks with a needle of 1 mm of diameter in order 
to achieve 80% epithelial cell purity in each sample. We isolated with the 
MiniCore puncher 1 core of cancer, 1 core of non-neoplastic tissue and 1 
core, when present, of PIN. Then total RNA was isolated with 
MasterPure™ Complete DNA and RNA Purification Kit (Epicentre 
Biotechnologies, Madison, WI, USA) following the manufacturer's 
instructions. From samples obtained with the LCM, we extracted and 
quantified total RNA as previously described. RNA was quantified 
spectrophotometrically and stored at -80°C in bioPur safe lock tubes. We 
collected in all RNA from 442 human samples (192 patients), 5 cell lines 
and 5 mice. 
3.5. Micro Fluidic Card and qRT-PCR 
From samples obtained with the LCM, we polled RNA from 5 mice and 
performed a low-density array platform (TaqMan® Array Rodent MicroRNA, 
Micro Fluidic Card Applied Biosystems, ABI PRISM® 7900HT) that allows 
to detect simultaneously about 700 miRNAs including endogenous small 
RNAs (snoRNA). We evaluated the differential expression of epithelial and 
stromal component of adenocarcinoma and PIN. 
Figure 16 summarizes qRT-PCR chemistry. We performed retro-
transcription with 40 ng (TRAMP mouse samples) of RNA using Megaplex 
RT primer poll A and B Rodent and the Taqman MicroRNA Reverse 
Transcription kit (Applied Biosystems, Life Technologies, Carlsbad, CA, 
USA). RT product was amplified with Pre-amplification primers pool. We 
analyzed with the same platform (TaqMan® Array Human MicroRNA) the 
miRNA expression profile in the cell lines (RWPE-1, BPH-1, LNCap, DU145 
and PC3) and reverse transcription was performed with 1µg of RNA. For 
the validation, we ordered a custom RT primers pool and 19 microRNA 
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Card custom (Micro Fluidic Card Applied Biosystems) designed with 23 
miRNA spotted. This platform allowed analyzing 23 miRNA in 8 samples 
per card simultaneously (Figure 15). 500 ng of RNA were reverse 
transcribed, and RT products were amplified with Pre-amplification primers 
pool. Housekeeping genes were snoRNA135 and snoRNA202, for TRAMP 
mouse analysis, MammU6, RNU44, RNU48 for cell line analysis, and 
MammU6 for human samples.  
 
 
Figure 15 : Card custom design with miRNA assay ID (left) and Microfluidic Card 
procedure (right) 
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Figure 16: qRT-PCR scheme. A: reverse transcription B: Pre-amplification reaction 
C: Real Time PCR 
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3.6. Immunohistochemistry (IHC) 
For each TMA block, 4µm-thick sections were stained with RUNX2 primary 
antibody (Novus Biologicals NBP1-01004) 1:1000 using citrate buffer in 
antigen retrieval step. Immunohistochemistry was performed using 
Benchmark Ultra Roche Ventana immunostainer. Endogenous peroxidase 
activity was blocked by hydrogen peroxide (0,3%) for 10 minutes. The 
chromogen diaminobenzidine (DAB) was incubated for 8 min at room 
temperature. All slides were counterstained with haematoxylin. 
A pathologist blinded to clinical data evaluated immunohistochemical 
results. Percentage and localization of immunoreactive cells were 
calculated by averaging out replicates of tumor cores. 
3.7. Derivation of fibroblasts 
We collected from radical prostatectomy tissue samples in order to derivate 
fibroblasts associated with the tissue. After surgery, we immediately 
collected the sample. A pathologist selected and area of interest and then 
we cut with at cryostat a frozen sections in order to identify normal and 
cancer tissues. Once identified the tissue of interest we transferred the 
piece under a laminar flow hood reserved to tissue culture. We cut up the 
prostate, normal or cancer, in small pieces in a plate with a sterile blade 
and let dry for 1 hour in incubator at 37°C 5% CO2. When the tissue 
adhered to the plate, we added 5mL of tissue culture medium mixture 
(HAM F12 GIBCO with 20% FBS, 10% Pen/Strep, 1% amphotericin B, 
0,2% Kanamycin) and incubated at 37°C 5% CO2. The day after we 
changed the media adding DMEM supplemented with 10% FBS and 1% 
Pen-Strep. 
After several days, fibroblasts associated with the tissue started growing on 
the plate. Once at confluence, we remove the tissue and split fibroblasts in 
a new plate with fresh media and we treated for 3 times every change of 
media with 1% of mycoplasma removal.  
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In all, we collected and cryopreserved 5 CAF lines and 3 NAF lines. For 
each line, we extracted RNA with the protocol above.  
3.8. Data analysis 
Expression data from qRT-PCR were first analyzed with DataAssist™ 
Software (Applied Biosystem). Mammary U6 was the housekeeping gene. 
The comparative Ct method (2−ΔCt) was used for the relative quantification 
(RQ) and miRNA RQs were median normalized and log2-transformed. In 
order to compare tissue classes, we used BrB Array tool. In cell lines, we 
compared miRNA expression data of cancer, hyperplastic and normal cell 
lines. Comparison was performed also between AR sensitive and 
insensitive cancer. 
MiRNAs expressed in at least one sample group were imported in dChip 
software (DNA-Chip Analyzer, www.dchip.org) for unsupervised 
hierarchical clustering. 
For human samples (n=58 patients), data were analyzed by means of two-
sided unpaired t tests using a GraphPad Prism© 5 software package for 
Windows. Data are expressed as the mean ± SD or mean ± SEM of 
multiple independent experiments. A p value of ≤0.05 was considered 
statistically significant. 
IHC evaluation of percentage and localization of immunoreactive cells was 
calculated by averaging out replicates of tumor cores. Data analysis was 
performed thought ROC curves (MedCalc© software), in order to 
discriminate between three categories (cancer normal and PIN). Evaluation 
was performed considering separately nuclear and cytoplasmic staining. 
ROC analysis was also performed with 4 miRNA of interest in order to 
define a cut-of for high and low protein or miRNA expressors as described 
in result section. Chi-square analysis was performed to compare tissue 
classes and histopathological parameters. A p value <0.05 was considered 
statistically significant. 
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4. RESULTS AND DISCUSSION 
4.1. Cell lines 
To identify miRNA potentially involved in prostate cancer progression we 
first compared the PCa cell lines (LNCap, DU145 and PC3) with the non-
malignant ones (RWPE-1 and BPH-1). In all, we found 23 miRNAs 
differentially expressed (Table 8). miRNA selection for validation in human 
samples was based on differences of expression levels in more aggressive 
cancer cell lines and androgen sensitive cancer cell line. Figure 17 shows 
miRNA clustering in cell lines and Figure 18 show dendrogram of cell lines 
clustering, using centered correlation and average linkage. 
 
 
Table 8: 23 miRNA selected in cell lines. Expression data are Log2 transformed  
miRNA RWPE-1 BPH1 LNCap DU145 PC3 
hsa-let-7c 1.26 -1.61 6.65 -6.22 -5.88
hsa-miR-100# 4 0.12 4.03 -1.95 -2.82
hsa-miR-130a 1.26 -1.08 -10.15 -1.26 -1.56
hsa-miR-135b 1.26 -1.83 -4.68 -0.81 -0.41
hsa-miR-138 1.26 1.79 -1.8 4.32 5.24
hsa-miR-193a-5p 1.26 -8.64 -0.5 -3.56 -3.97
hsa-miR-203 1.26 -4.06 -0.54 -5.77 -6.89
hsa-miR-205 1.26 -1.57 -13.92 -14.77 -14.88
hsa-miR-218 1.26 -7.91 -2.93 -4.27 -4.7
hsa-miR-224 1.26 -3.23 -6.36 -13.09 -13.19
hsa-miR-22 1.26 -7.26 -0.08 -2.25 -1.33
hsa-miR-31 1.26 -1.48 -18.06 0.53 0.03
hsa-miR-331-5p 1.26 5.22 2.32 9.11 11.33
hsa-miR-34b -5.55 0.12 -2.11 3.3 3.49
hsa-miR-34c-5p 1.26 -2.7 -3.78 3.43 4.52
hsa-miR-450b-5p 1.26 2.2 3.42 6.55 4.84
hsa-miR-452 1.26 -0.85 -9.98 -10.83 -10.93
hsa-miR-489 1.26 -3.6 -4.51 6.07 4.03
hsa-miR-532-5p 1.26 -6.84 2.34 0.46 0.9
hsa-miR-542-5p 1.26 2.2 1.12 7.18 7.89
hsa-miR-577 -3.84 0.12 -4.5 1.11 3.09
hsa-miR-708 1.26 -4.79 -12.88 -13.73 -13.83
hsa-miR-886-3p 1.26 2.2 1.82 13.01 13.04
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Figure 17: miRNA clustering 
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Figure 18:  Dendrogram of cell lines clustering 
 
Several studies described miRNA profiling in prostate cancer cell lines, with 
controversial results.  
In an early study, Jiang et al.[97] analyzed the abundances of selected 
miRNAs in PCa cell lines using real-time PCR. They found that androgen 
independent (AI) cell lines exhibited 4-fold increased expression of miR-100 
and androgen-dependent (AD) LNCaP cells had 53-fold increased levels of 
let-7c, relative to control cells, according with our results (Table 8). Kore et 
al.[98] employed locked nucleic acids (LNA)-labelled miRNA probes to 
detect let-7c expression in human PCa samples. They found that let-7c was 
clearly present in PCa cells. Lin et al. [99] compared miRNA expression 
profiles between AI and AD PCa cells. MiR-205 was the most described in 
PCa and in a recent study [100], Boll at al. observed that miR-130a, miR-
203 and miR-205 simultaneously interfere with two primary oncogenic 
pathways in prostate carcinoma, AR and MAPK signaling. They found 
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these miRNAs simultaneously downregulated in the disease and suggest a 
synergistic effect as tumor suppressors in PCa [100]. 
4.2. Human samples 
To assess the in-vivo relevance of these results, we analyzed this 23 
miRNA selected in a larger case study of 58 patients to confirm our results 
and to find a correlation between miRNA expression profile, tumor staging 
and patients’ follow up. 13 miRNA were confirmed statistically, with a p 
value <0.05. We compared normal, cancer and PIN samples. MiR-130a, 
miR-218, miR-532, miR-542-5p, miR-489 and let-7c showed 
downregulation in PIN compared with matched normal tissue. MiR-135b, 
miR-193-5p, miR-250, miR-224 and miR452 showed downregulation in 
PCa compared with normal. Finally, we observed a loss miR-31 in PCa 
compared to precancerous lesions (PIN). Statistical analysis was 
performed with GraphPad Prism5 software, and p values are displayed in 
Table 9. All data are Log2 transformed and the comparison of expression 
levels was a paired t test (p value <0.05 was considered significant).  
MiR-130a, miR-203 and miR-205 were previously reported as 
downregulated in prostate cancer. These miRNAs interfere with two major 
oncogenic pathways in prostate carcinoma, AR and MAPK signaling [100]. 
They suggest a synergistic effect of these three miRNA as tumor 
suppressors in PCa. In our sample set we found that miR-130a is down 
regulated in PIN compared with normal (p=0.006), miR-203 didn’t show 
differences statistically significant, and miR-205 was down regulated 
(p=<0.0001), as reported in several papers [72], [101], [102], [103]. As 
previously reported, downregulation of miR-205 correlate with tumor stage 
and Gleason score. Indeed, we compared the expression level with 
clinicopathological parameters and, as shown in  
Results and discussion 
56 
 
Figure 19, miR-205 is strongly downregulated in high Gleason score PCa. 
In this validation set, we re-analyzed 2 cell lines (RWPE-1 and PC3) that 
followed the same trend as in TaqMan® Array Cards.  
 
 
Table 9: Average Log2 expression level. 13 miRNA are downregulated in cancer 
progression (paired t test p <0.005) 
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Figure 19: A: miR-205 downregulation in high Gleason score PCa (p=0.0321)B: 
miR-205 expression in cell lines 
Our results confirm expression data previously reported in literature but for 
some miRNA we found differences in expression not previously described.  
In a recent study, they found a different signature in the high-grade tumors 
(Gleason score ≥ 8) when compared with tumors Gleason score 6. Up 
regulation of miR-122, miR-335, miR-184, miR-193, miR-34, miR-138, miR-
373, miR-9, miR-198, miR-144 and miR-215 and down-regulation of miR-
96, miR-222, miR-148, miR-92, miR-27, miR-125, miR-126, miR-27 were 
found in the high grade tumors. [104]. In our results about miR-193a, we 
did not find any differences between high and low Gleason score cancer 
and we reported a down regulation in tumor (p=0.0021) instead of up 
regulation. In contrast with these results, we found a downregulation of 
miR-138 in cancer. Leite et al. [105] observed that miR-let7c, miR-100, and 
miR-218 were significantly overexpressed in localized high GS, pT3 
prostate cancer in comparison with metastatic carcinoma. Our results show 
only a miR-218 decrease in PIN compared with normal tissue Table 9.  
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MiR-452 was previously described as overexpressed in cancer 
stem/progenitor cells of prostate [106], but in our results was strongly 
downregulated (p=<0.0001). 
Finally, comparing the expression of 9 miRNAs lost in tumor progression 
(hsa-miR-135b, -193a-5p, -205, -224, -22, -34b, -34c-5p, -452, -886-3p), for 
three of these (hsa-miR-34b, -34c-5p and -886-3p) we observed a different 
expression pattern, because they were overexpressed in cell lines (Figure 
20). 
 
Figure 20: 9 miRNA downregulated in PCa human samples 
4.3. RUNX2 expression on TMA 
Therefore, in our study we also investigate the expression levels of RUNX2 
in human Tissue microarray of prostate tissue (normal, cancer and PIN) 
and examine the correlation between RUNX2 levels and the 
clinicopathological characteristics of PCa. Runx2, a key regulator involved 
in the bone tropism of metastatic cells, when abnormally expressed in 
tumor cells, has pathological functions that are deregulated compared to 
normal cells: Runx2 is no longer antiproliferative, and instead appears to 
have oncogenic properties. 
-2
-1.5
-1
-0.5
0
0.5
1
1.5
N PIN K
hsa-miR-135b
hsa-miR-193a-5p
hsa-miR-205
hsa-miR-224
hsa-miR-22
hsa-miR-34b
hsa-miR-34c-5p
hsa-miR-452
hsa-miR-886-3p
Results and discussion 
59 
 
Immunohistochemical staining to evaluate RUNX2 protein levels in PCa 
yielded results conflicting with those of previous studies. Chua et al. [107] 
analyzed RUNX2 protein levels in specimens from 39 BPH patients, 8 high-
grade prostatic intraepithelial neoplasia cases and 128 PCa tissues by 
immunohistochemical staining. These authors reported that RUNX2 was 
undetectable or showed low cytoplasmic expression in BPH (2.6%), 
whereas the protein was detected in the cytoplasm in 84.4% of PCa 
tissues. In addition, no correlation between cytoplasmic expression of 
RUNX2 and prognostic significance was reported in their study. In another 
study, Akech et al. [86] analyzed a PCa tissue microarray through 
immunohistochemistry and reported that the majority of non-neoplastic 
tissues and prostatic intraepithelial neoplasia lesions were negative for 
RUNX2, whereas 48% of the primary tumors and 46% of metastatic tissues 
were RUNX2 positive. In contrast to these two reports, Yun et al. [84] 
observed cytoplasmic RUNX2 protein expression in all BPH tissues with 
similar patterns of staining with moderate to strong intensity. The 
correlation was also observed between RUNX2 mRNA expression and the 
cytoplasmic staining intensity of the protein [84]. 
Similar immunohistochemical findings to those of the current study were 
reported by Brubaker et al. [88], who analyzed human prostate tissues 
obtained from 16 radical prostatectomies and 12 rapid autopsy specimens, 
and reported the detection of the RUNX2 protein in both PCa cells and 
normal glands.  
Interestingly, nuclear localization of RUNX2 was significantly associated 
with metastatic disease compared with the cases in which RUNX2 was not 
detected in the nucleus, which is in agreement with the results reported by 
Chua et al. [107]. According to their study, RUNX2 nuclear expression was 
associated with higher Gleason score (greater than or equal to 7), higher 
PSA levels and an increased risk of metastasis. Yun et al. results 
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suggested that nuclear expression of RUNX2 could be used as a 
prognostic marker to predict metastasis in advanced PCa.  
Figure 21: ROC curve analysis of nuclear and cytoplasmic expression of RUNX2 
According with Chua and Yun [107][84], evaluating expression of RUNX2 
on TMA, we found through ROC curve analysis that only nuclear staining 
could discriminate between normal and cancer tissue, with a P value 
<0.0001 (AUC: 0.762, 95%, Confidence interval: 0.715 to 0.805) with 79,3% 
of specificity and 74,1% of sensitivity (Figure 21). Once divided in high- 
and low- RUNX2 expressors, based on ROC cut-of, we verified correlation 
between protein expression and clinical data. We found a correlation with 
tumor extension. RUNX2 expression was lower in low grade cancer (T2) 
and higher in high grade cancer (T3-T4) with a p value of 0.0049 (Figure 
22). We also found a correlation statistically significant, considering 
capsular invasion (Wheeler classification). RUNX2 expression was low in 
prostate cancer with low capsular invasion (L1-L2) with a p value of 0.0151 
(Figure 23)  
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 RUNX2 
HIGH 
RUNX2 
LOW 
 
T HIGH 59 9 68 (36.0%) 
T LOW 81 40 121 (64.0%) 
 140 49 189 
-74.10% -25.90% 
 
Figure 22: Chi-square analysis of nuclear expression of RUNX2 correlate with 
tumor stage (p=0.0049) 
RUNX2 NUCLEAR 
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 RUNX2 
HIGH 
RUNX2 
LOW 
 
Wheeler HIGH 50 8 58 (33,0%) 
Wheeler LOW 80 38 118 (67,0%) 
 130 
(73,9%) 
46 
(26,1%) 
176 
 
Figure 23: Chi-square analysis of nuclear expression of RUNX2 correlate with 
capsular invasion (p=0.0151) 
  
RUNX2 NUCLEAR 
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Was also evaluated with Chi-square analysis, the correlation with cellular 
localization of RUNX2 (nuclear, cytoplasmic and co-localization). We 
observed a strong nuclear and co-localized expression of RUNX2 in cancer 
tissue, a cytoplasmic localization in normal and PIN tissue, with a p value 
<0.0001 (Figure 24). 
 
Figure 24: RUNX2 localization 
 
In Figure 25 and Figure 26 are displayed illustrative pictures of nuclear 
staining in cancer and cytoplasmic staining in normal tissue respectively, at 
20X magnification. 
      NUCLEAR         CYTOPLASMIC       CO-
LOCALIZED 
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Figure 25: Illustrative nuclear staining of RUNX2 in cancer (20X magnification) 
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Figure 26: Cytoplasmic staining of RUNX2 in normal tissue (20X magnification) 
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4.4. Four miRNA candidate target RUNX2 protein 
We selected from literature and miRNA database, 4 miRNAs that target 
RUNX2 (miR-203, -205, -218 and -224). 
Saini et al. demonstrate trough luciferase assay, that miR-203 regulates the 
expression of several bone-specific effectors including Runx2, a master 
regulator of bone metastasis [108]. Gay et al demonstrate that the human 
miRNA-218 targets RUNX2 expression [109]. Finally, Zhang et al found, 
trough luciferase-based miRNA expression reporter assays, seven RUNX2-
targeting miRNAs: miR-23a, miR-30c, miR-34c, miR-133a, miR-135a, miR-
205, and miR-217 [110]. 
Mir-224 was only predicted to target RUNX2 (miRDB). This evidences 
supported our purpose to evaluate miRNA-target interaction  
ROC curves analysis shows that 3 miRNA (miR-205, -218, -224) can 
discriminate between normal and PIN (Figure 27,Table 10). 
 
miRNA AUC 95% Confidence interval Significance level P  
miR-203 0.573 0,447 to 0,692 ns 
miR-205 0.641 0,516 to 0,754 0.039 
miR-218 0.64 0,514 to 0,753 0.0429 
miR-224 0.851 0,744 to 0,926 <0.0001 
 
Table 10: Values of ROC curves analysis (AUC: Area under curve), discrimination 
between normal and PIN. 
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Figure 27: ROC curve of miR-203, -205, -218 and -224, discrimination between 
normal and PIN. 
 
Then we evaluated the correlation between expression of miRNAs and 
RUNX2 staining on TMA and our results show that miR-205 and miR-218 
expression inversely related to nuclear expression of RUNX2. When 
miRNAs expression decreases, there is an increased nuclear expression of 
RUNX2, and conversely, when miRNAs are highly expressed, RUNX2 
nuclear staining decrease (Figure 28). P values of Chi-square analysis 
were statistically significant (miR-205 p= 0.0011 and miR-218 p=0.0096). 
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Figure 28: miR-205 and -218 expression is inversely correlated with nuclear 
localization of RUNX2 (p value= 0.0011 and 0.0096) 
 
P= 0.0011 
P= 0.0096 
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4.5. TRAMP mouse 
Whereas stroma adjacent to tumor cells has gained considerable 
importance in determining patient response to therapy and disease 
progression in several human cancers, including PCa, we also evaluate 
with a statistical analysis different expression of miRNAs in TRAMP model 
between cancer and PIN epithelial component, in order to find miRNA well 
conserved that could have a role in cancer therapy. 
Figure 29 show a scatter plot of miRNA up and down regulated in the 
epithelial component between cancer and PIN. MiRNA differentially 
expressed are listed in Table 11. We found 52 miRNAs deregulated, 
among which 10 miRNAs upregulated in PIN and 42 upregulated in cancer 
epithelium. 
. 
 
Figure 29: Scatter plot of miRNA expression in stromal component of PIN and 
cancer tissue of TRAMP mouse at 24 weeks 
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Table 11: miRNA up and down regulated in epithelial component of PIN in TRAMP 
mouse at 24 weeks. 
We also compared our previous data with miRNA expression in TRAMP 
mouse. We found some comparable expression trend. MiR-138, miR-31, 
miR-34b and miR-34c were downregulated in PCa and in LNCap cells, but 
were upregulated in cancer epithelium of TRAMP mouse such as in DU145 
and PC3, due to the aggressiveness of cancer in this mouse model.  
These preliminary results will be used to perform further analysis on 
epithelium-stroma interaction in prostate cancer. 
4.6. CAF and NAF 
Transfection efficiency was tested by GFP in CAF (cancer-associated 
fibroblasts) and NAF (normal associated fibroblasts) for further applications. 
Our results (Figure 31) show a good rate of transfected cells. In CAF, more 
than was the confluence less was the transfection efficiency (Figure 30) 
and in NAF we observed a stable rate of transfection during 96 hours of 
culture. The rate of transfected cells was higher in CAF than in NAF. We 
assessed this preliminary experiment in order to modulate miRNA 
expression in CAFs and NAFs. 
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Figure 30: Transfection efficiency test by GFP in CAF (Cancer associate 
Fibroblasts). Panel A, C and E show bright field at 10x magnification of CAF cell 
line at 3 different rate of confluence. More than was the confluence less was the 
transfection efficiency (Panel B, D, F) 
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Figure 31: Transfection efficiency test by GFP in NAF (Normal associate 
Fibroblasts). Panel A, C and E show bright field at 10x magnification of NAF cell 
line at 24-48-96h of culture. Transfection efficiency (Panel B, D, F) was stable. 
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CONCLUSION 
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Different experimental approaches used in our research, highlight that, 
unlike cell lines, human prostate cancer express lower miRNA levels, 
compared with normal prostatic parenchyma. These data imply that, 
depending on the molecule under examination, the cell lines represent a 
reliable or not model of in vivo tumorigenesis Indeed, 3 miRNA that we 
expected to find upregulated, were downregulated in human PCa. We 
found in all 13 miRNA downregulated in cancer and 9 miRNA (hsa-miR-
135b, -193a-5p, -205, -224, -22, -34b, -34c-5p, -452, -886-3p), with a p 
value statistically significant, downregulated in cancer progression (normal, 
PIN and cancer, progressively). As several studies reported, we observed a 
synergetic loss of miRNA with onco-suppressive role (miR-205, -224, -218) 
and simultaneous increase of Runx2 protein. This finding has important 
implications for disease progression, which will be evaluated in next steps 
of research project.  
Our analysis indicates that miR-205 is a putative marker of disease 
aggressiveness and especially identifies 9 miRNAs prematurely lost in early 
precancerous lesions (PIN), compared to normal parenchyma.  
Validation of this data with independent case studies will confirm these 
molecules as novel biomarkers of cancer, in order to support the PSA 
assessment.  
Furthermore, the study of miRNAs stromal showed a profound deregulation 
of these molecules in the tumor microenvironment than in non-neoplastic. 
This result emphasizes the molecular point of view of the importance of the 
stroma in supporting the survival and tumor growth and provides a possible 
alternative therapeutic strategy, targeted to epithelial stromal cells instead, 
in order to induce regression of the disease. Further studies are needed to 
evaluate the role of miRNAs in the interaction between tumor epithelium 
and surrounding stroma. 
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